Verastem, Inc.
NASDAQ: VSTM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel W. Paterson
- Employees
- 78
- Headquarters
- Needham, United States
- IPO year
- 2012
- Market cap
- $266.9M
- Website
- https://www.verastem.com
Loading VSTM…
Loading profile data…Frequently asked questions about VSTM
What does Verastem, Inc. (VSTM) do?
Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrup...
Where does VSTM trade?
Verastem, Inc. (VSTM) trades on the NASDAQ Global Market.
What sector is VSTM in?
Verastem, Inc. (VSTM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Verastem, Inc.?
Daniel W. Paterson is the chief executive officer of Verastem, Inc. (VSTM).
Where is Verastem, Inc. headquartered?
Verastem, Inc. is headquartered in United States.
Does VSTM pay a dividend?
Verastem, Inc. (VSTM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VSTM go public?
Verastem, Inc. (VSTM) completed its initial public offering in 2012.